Skip to main content
SpringerLink
Log in

Chemoprevention of Breast Cancer: Current and Future Prospects

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

The groundwork for making the concept of breast cancer chemoprevention a clinical reality began over a century ago. Although tamoxifen's first clinical use was for the treatment of breast cancer, the earliest animal studies with the drug provided the scientific basis for chemoprevention. The extensive clinical experience, safety and laboratory data have made tamoxifen the current standard-of-care for the prevention of breast cancer in women at elevated risk. The STAR trial will address the value of raloxifene as a chemopreventative in postmenopausal women. Results will be available by 2005. Newer compounds are under development which hold the promise of expanded efficacy and narrower side-effect profile. These compounds will function as multifunctional medicines and will hold the promise of preventing breast and endometrial cancer, while providing the beneficial effects of preventing osteoporosis and coronary heart disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2: 104–107, 1896

  2. Boyd S: On oophorectomy in cancer of the breast. BMJ 2: 1161–1167, 1900

  3. Lacassagne A: Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 27: 217–225, 1936

    Google Scholar 

  4. Allen E, Doisy EA: An ovarian hormone: Preliminary report on its localization, extraction and partial purification and action in test animals. JAMA 81: 819–821, 1923

    Google Scholar 

  5. Dodds EC, Lawson W, Noble RL: Biological effects of the synthetic oestrogenic substance 4:4´-dihydroxy-alpha:beta-diethylstilbene. Lancet 1: 1938

  6. Robson JM, Schonberg A: Oestrous reactions including mating produced by triphenylethylene. Nature 140: 196, 1937

    Google Scholar 

  7. Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18: 387–414, 1962

    Google Scholar 

  8. Gorski J, Toft D, Shyamala G, Smith D, Notides A: Hormone receptors: Studies on the interaction of estrogen with the uterus. Recent Prog Horm Res 24: 45–80, 1968

    Google Scholar 

  9. Jensen EV, Suzuki T, Kawashima T, Stumpf WE, Jungblut PW, DeSombre ER: A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci USA 59: 632–638, 1968

    Google Scholar 

  10. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER: Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 34: 55–70, 1971

    Google Scholar 

  11. McGuire WL, Carbone PP, Volmer EP: Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975

    Google Scholar 

  12. Lerner LJ, Holthaus JF, Thompson CR: A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenylethanol. Endocrinology 63: 295–318, 1958

    Google Scholar 

  13. Greenblatt RB, Barfield WE, Jungck EC, Ray AW: Induction of ovulation with MRL-41 – preliminary report. JAMA178: 101–104, 1961

    Google Scholar 

  14. Jordan VC, Prestwich G: Binding of [3H]tamoxifen in rat uterine cytosols: A comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol Cell Endocrinol 8: 179–188, 1977

    Google Scholar 

  15. Jordan VC, Koerner S: Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11: 205–206, 1975

    Google Scholar 

  16. Cole MP, Jones CT, Todd ID: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br J Cancer 25: 270–275, 1971

    Google Scholar 

  17. Ward HW: Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. BMJ 2: 13–14, 1973

    Google Scholar 

  18. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424, 1976

    Google Scholar 

  19. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239–251, 1980

    Google Scholar 

  20. Gottardis MM, Jordan VC: The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020–4024, 1987

    Google Scholar 

  21. Jordan VC, Lababidi MK, Langan-Fahey S: Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83: 492–496, 1991

    Google Scholar 

  22. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer. Lancet 2: 282, 1985

    Google Scholar 

  23. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320: 479–484, 1989

    Google Scholar 

  24. Sporn MB, Dunlop NM, Newton DL, Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35: 1332–1338, 1976

    Google Scholar 

  25. Sporn MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36: 2699–2702, 1976

    Google Scholar 

  26. EBCTCG: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351: 1451–1467, 1998

    Google Scholar 

  27. Terenius L: Structure-activity relationships of antioestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina. Acta Endocrinol (Copenh) 66(Suppl): 431–447, 1971

    Google Scholar 

  28. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992

    Google Scholar 

  29. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DL: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115: 860–864, 1991

    Google Scholar 

  30. Pappas SG, Jordan VC: Raloxifene for the treatment and prevention of breast cancer? Expert Review of Anticancer Therapy 1: 334–340, 2001

    Google Scholar 

  31. Levenson AS, Jordan VC: Selective oestrogen receptor modulation: Molecular pharmacology for the millennium. Eur J Cancer 35: 1628–1639, 1999

    Google Scholar 

  32. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP: Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140: 5828–5840, 1999

    Google Scholar 

  33. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98–101, 1998

    Google Scholar 

  34. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 362: 93–97, 1998

    Google Scholar 

  35. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Torrisi R, Manetti L, Robertson C, De Palo G, Formelli F, Costa A, Veronesi U: Chemoprevention of breast cancer: The Italian experience. J Cell Biochem Suppl 34: 84–96, 2000

    Google Scholar 

  36. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388, 1998

    Google Scholar 

  37. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356: 1876–1881, 2000

    Google Scholar 

  38. Bentrem DJ, Jordan VC: Tamoxifen, raloxifene and the prevention of breast cancer. Minerva Endocrinologica 26: 1–13, 2001

    Google Scholar 

  39. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually [see comments]. J Natl Cancer Inst 81: 1879–1886, 1989

    Google Scholar 

  40. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91: 1541–1548, 1999

    Google Scholar 

  41. Cathacart CKJS, Pumroy CS, et al.: Clinical recognition and management of depression in node-negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 27: 277–281, 1993

    Google Scholar 

  42. Love RR, Cameron L, Connell BL, Leventhal H: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151: 1842–1847, 1991

    Google Scholar 

  43. Shariff S, Cumming CE, Lees A, Handman M, Cumming DC: Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect? Ann N Y Acad Sci 761: 365–368, 1995

    Google Scholar 

  44. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the national surgical adjuvant breast and bowel project P-1 study [In process citation]. J Clin Oncol 17: 2659, 1999

    Google Scholar 

  45. Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J: Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19: 1885–1892, 2001

    Google Scholar 

  46. Day R, Ganz PA, Costantino JP: Tamoxifen and depression: More evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 93: 1615–1623, 2001

    Google Scholar 

  47. Assikis VJ, Neven P, Jordan VC, Vergote I: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32A: 1464–1476, 1996

    Google Scholar 

  48. Jordan VC: Designer estrogens. Sci Am 279: 60–67, 1998

    Google Scholar 

  49. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32: 1031–1036, 1983

    Google Scholar 

  50. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, Falcone JF, Clemens JA: Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 27: 1057–1066, 1984

    Google Scholar 

  51. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, et al.: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93: 63–69, 1994

    Google Scholar 

  52. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L, Jr.: Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95: 104–110, 2000

    Google Scholar 

  53. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [see comments]. N Engl J Med 337: 1641–1647, 1997

    Google Scholar 

  54. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW: Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 177: 1458–1464, 1997

    Google Scholar 

  55. Jordan VC, Gapstur S, Morrow M: Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 93: 1449–1457, 2001

    Google Scholar 

  56. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G: Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45: 344–345, 1988

    Google Scholar 

  57. Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW, Jr.: Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88: 2047–2053, 2000

    Google Scholar 

  58. Lerner LJ, Jordan VC: Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture. Cancer Res 50: 4177–4189, 1990

    Google Scholar 

  59. Jordan VC, Phelps E, Lindgren JU: Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31–35, 1987

    Google Scholar 

  60. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation [see comments]. JAMA 281: 2189–2197, 1999

    Google Scholar 

  61. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65: 125–134, 2001

    Google Scholar 

  62. Jordan VC, Glusman JE, Powles TJ, Costa A, Morrow M, Norton L: Incident primary breast cancer are reduced by raloxifene: Integrated data from multicenter, double blind, randomized trials in 12,000 postmenopausal women Proc ASCO 122a (Abstract 466) 1998.

  63. Jordan VC, Glusman JE, Eckert S, Lippman ME, Powles TJ, Costa A, Morrow M, Norton L: Raloxifene reduces incident primary breast cancers. Integrated data from multicenter double blind, placebo controlled, randomized trials in postmenopausal women. Breast Cancer Res Treat 50: 227, 1998

    Google Scholar 

  64. Jordan VC, Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20: 253–278, 1999

    Google Scholar 

  65. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (multiple outcomes of raloxifene evaluation) randomized trial. JAMA 287: 847–857, 2002

    Google Scholar 

  66. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women [see comments]. JAMA 279: 1445–1451, 1998

    Google Scholar 

  67. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605–613, 1998

    Google Scholar 

  68. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA: Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287: 216–220, 2002

    Google Scholar 

  69. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, et al.: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556–2566, 1995

    Google Scholar 

  70. Maenpaa J, Holli K, Pasanen T: Toremifene. Where do we stand? Eur J Cancer 36(Suppl 4): S61–S62, 2000

    Google Scholar 

  71. Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 18: 3487–3494, 2000

    Google Scholar 

  72. Rosati RL, Da Silva Jardine P, Cameron KO, Thompson DD, Ke HZ, Toler SM, Brown TA, Pan LC, Ebbinghaus CF, Reinhold AR, Elliott NC, Newhouse BN, Tjoa CM, Sweetnam PM, Cole MJ, Arriola MW, Gauthier JW, Crawford DT, Nickerson DF, Pirie CM, Qi H, Simmons HA, Tkalcevic GT: Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 41: 2928–2931, 1998

    Google Scholar 

  73. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Thompson DD: Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 139: 2068–2076, 1998

    Google Scholar 

  74. Willson TM, Henke BR, Momtahen TM, Charifson PS, Batchelor KW, Lubahn DB, Moore LB, Oliver BB, Sauls HR, Triantafillou JA, et al.: 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 37: 1550–1552, 1994

    Google Scholar 

  75. Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V: Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 142: 838–846, 2001

    Google Scholar 

  76. Connor CE, Norris JD, Broadwater G, Willson TM, Gottardis MM, Dewhirst MW, McDonnell DP: Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 61: 2917–2922, 2001

    Google Scholar 

  77. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Merand Y, Belanger A, Labrie C, Labrie F: (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl2,2-dimethylpropanoate (EM-800): A highly potent, specific, and orally active nonsteroidal antiestrogen. J Med Chem 40: 2117–2122, 1997

    Google Scholar 

  78. Luo S, Labrie C, Belanger A, Candas B, Labrie F: Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050). Breast Cancer Res Treat 49: 1–11, 1998

    Google Scholar 

  79. Martel C, Labrie C, Belanger A, Gauthier S, Merand Y, Li X, Provencher L, Candas B, Labrie F: Comparison of the effects of the neworally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology 139: 2486–2492, 1998

    Google Scholar 

  80. Couillard S, Gutman M, Labrie C, Belanger A, Candas B, Labrie F: Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res 58: 60–64, 1998

    Google Scholar 

  81. Martel C, Picard S, Richard V, Belanger A, Labrie C, Labrie F: Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol 74: 45–56, 2000

    Google Scholar 

  82. Schafer JI, Liu H, Tonetti DA, Jordan VC: The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res 59: 4308–4313, 1999

    Google Scholar 

  83. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU: LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287: 1–7, 1998

    Google Scholar 

  84. Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peer C, Wang Y, Sporn MB: Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61: 8412–8415, 2001

    Google Scholar 

  85. MacGregor-Schafer J, Lee E-S, Dardes R, Bentrem D, O'Regan RM, De los Reyes A, Jordan VC: Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY 353381) and LY 117018 in tamoxifen-stimulated breast cancer xenografts. Clin Cancer Res 7: 2505–2512, 2001

    Google Scholar 

  86. Munster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C: Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 19: 2002–2009, 2001

    Google Scholar 

  87. Peto R, Boreham J, Clarke M, Davies C, Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 355: 1822, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Molecular Pharmacology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL, USA

    Sam G. Pappas

  2. Biological Chemistry, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL, USA

    V. Craig Jordan

Authors
  1. Sam G. Pappas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pappas, S.G., Craig Jordan, V. Chemoprevention of Breast Cancer: Current and Future Prospects. Cancer Metastasis Rev 21, 311–321 (2002). https://doi.org/10.1023/A:1021219212638

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021219212638

Search

Navigation